Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Ligelizumab for chronic spontaneous urticaria
 
  • Details

Ligelizumab for chronic spontaneous urticaria

Journal
New England Journal of Medicine
Journal Volume
381
Journal Issue
14
Pages
1321-1332
Date Issued
2019
Author(s)
Maurer M.
Gim?nez-Arnau A.M.
Sussman G.
Metz M.
Baker D.R.
Bauer A.
Bernstein J.A.
Brehler R.
CHIA-YU CHU  
Chung W.-H.
Danilycheva I.
Grattan C.
H?bert J.
Katelaris C.
Makris M.
Meshkova R.
Savic S.
Sinclair R.
Sitz K.
Staubach P.
Wedi B.
L?ffler J.
Barve A.
Kobayashi K.
Hua E.
Severin T.
Janocha R.
DOI
10.1056/NEJMoa1900408
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073056627&doi=10.1056%2fNEJMoa1900408&partnerID=40&md5=026eb361f1eab1a33a0a6c7ae9db13b8
https://scholars.lib.ntu.edu.tw/handle/123456789/434856
Abstract
BACKGROUND In the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control. Ligelizumab is a next-generation high-affinity humanized monoclonal anti-IgE antibody. Data are limited regarding the dose–response relationship of ligelizumab and the efficacy and safety of ligelizumab as compared with omalizumab and placebo in patients who have moderate-to-severe chronic spontaneous urticaria that is inadequately controlled with H1-antihistamines at approved or increased doses, alone or in combination with H2-antihistamines or leukotriene-receptor antagonists. METHODS In a phase 2b dose-finding trial, we randomly assigned patients to receive ligelizumab at a dose of 24 mg, 72 mg, or 240 mg, omalizumab at a dose of 300 mg, or placebo, administered subcutaneously every 4 weeks for a period of 20 weeks, or a single 120-mg dose of ligelizumab. Disease symptoms of hives, itch, and angioedema were monitored by means of weekly activity scores. The main objective was to determine a dose–response relationship for the complete control of hives (indicated by a weekly hives-severity score of 0, on a scale from 0 to 21, with higher scores indicating greater severity); the primary end point of this response was assessed at week 12. Complete symptom control was indicated by a weekly urticaria activity score of 0 (on a scale from 0 to 42, with higher scores indicating greater severity). Safety was analyzed throughout the trial. RESULTS A total of 382 patients underwent randomization. At week 12, a total of 30%, 51%, and 42% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of hives, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group. A dose–response relationship was established. At week 12, a total of 30%, 44%, and 40% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of symptoms, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group. In this small and short trial, no safety concerns regarding ligelizumab or omalizumab emerged. CONCLUSIONS A higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelizumab therapy of 72 mg or 240 mg than with omalizumab or placebo. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT02477332.) ? 2019 Massachusetts Medical Society.
SDGs

[SDGs]SDG3

Other Subjects
ligelizumab; omalizumab; placebo; antiallergic agent; antiidiotypic antibody; immunoglobulin E; ligelizumab; monoclonal antibody; omalizumab; adult; aged; Article; chronic urticaria; clinical assessment; controlled study; disease severity; dose response; double blind procedure; drug efficacy; drug safety; female; headache; health care quality; human; injection site erythema; major clinical study; male; multicenter study; phase 2 clinical trial; priority journal; randomized controlled trial; skin disease assessment; symptom; treatment duration; treatment response; viral upper respiratory tract infection; blood; chronic disease; clinical trial; comparative study; drug administration; immunology; middle aged; patient acuity; remission; urticaria; young adult; Adult; Aged; Anti-Allergic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Immunoglobulin E; Male; Middle Aged; Omalizumab; Patient Acuity; Remission Induction; Urticaria; Young Adult
Publisher
Massachussetts Medical Society
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science